ENTITY
Zai Lab Ltd

Zai Lab Ltd (ZLAB US)

131
Analysis
Health CareChina
Zai Lab Limited operates as a bio-pharmaceutical company. The Company researches and develops therapeutic technology for antibody-based oncology, autoimmune, and infectious diseases treatments. Zai Lab also manufactures drugs in the form of capsules, injections, and liquids. Zai Lab serves patients worldwide.
more
Refresh
bullishChindata Group
27 Sep 2020 08:46

ECM Weekly (27 September 2020) - Ant Group, Chindata, SCG Packaging, JHBP/Genor, Neuedu, UTI AMC

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Deal...

Share
bullishZai Lab Ltd
25 Sep 2020 09:32

Zai Lab HK Trading - Interest and Behaviour in Line with Huazhu, Highest Concentration so Far

Zai Lab Ltd (ZLAB US) plans to raise around US$1bn in its secondary listing in Hong Kong. We have covered the company's listing and some of its...

Logo
421 Views
Share
bullishHuazhu Group
21 Sep 2020 16:46

Huazhu Group Secondary Listing: Trading Debut

Yum China Holdings Inc (9987 HK) will commence trading in Hong Kong on Thursday, 10 September. Yum China Holdings, Inc (YUMC US) priced its Hong...

Logo
281 Views
Share
bullishHuazhu Group
21 Sep 2020 10:05

Huazhu HK Secondary Listing Trading - Lowest Coverage, Biggest Correction, Highest Concentration

Huazhu Group (HTHT US) raised around US$900m in its secondary listing in Hong Kong. I have covered the background of the deal in my earlier...

Logo
289 Views
Share
bullishZai Lab Ltd
20 Sep 2020 03:58

Zai Lab Secondary Listing: HK-ADS Premium/​​(Discount) Views

ZTO Express (ZTO US) has launched a $1.6 billion secondary listing in Hong Kong. We previously outlined our views on ZTO Express’ fundamentals and...

Logo
267 Views
Share
x